Use of heart failure drug restricted by FDA to 30 days

05/2/2013 | CardiovascularBusiness.com

The FDA ordered doctors to restrict the use of Otsuka Pharmaceuticals' Samsca, or tolvaptan, to 30 days or less because of potential liver damage that could result in organ transplantation or death. The treatment is indicated for clinically significant euvolemic and hypervolemic hyponatremia tied to conditions including heart failure. The agency also discourages the drug's use in patients with underlying liver disease.

View Full Article in:

CardiovascularBusiness.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR